Calgary-based Providence Therapeutics’ COVID-19 vaccine candidate is showing encouraging results in a Phase 1 trial. The candidate is a messenger RNA (mRNA) vaccine, the same type as ones already approved from Pfizer and Moderna. Among 60 participants, those who received the vaccine rather than placebo showed antibodies after 28 days and 100% “blocking activity” against COVID-19 after 42 days. The company will next undertake a Phase 2 trial in locations that are still to be determined.